Drug Profile
Research programme: AAV-based gene therapeutics - Tamid Bio
Alternative Names: AAV gene therapy - Tamid Bio; Adenoviral-associated vector-mediated gene therapy - Tamid Bio; Tamid-001Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Tamid Bio; University of North Carolina at Chapel Hill
- Class Gene therapies
- Mechanism of Action Gene transference; Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Keratoplasty rejection; Mucopolysaccharidosis I; Muscular dystrophies
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Keratoplasty-rejection in USA
- 28 Jan 2022 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-I in USA
- 28 Jan 2022 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA